X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs ALKEM LABORATORIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES ALKEM LABORATORIES SUVEN LIFESCIENCES/
ALKEM LABORATORIES
 
P/E (TTM) x 20.7 - - View Chart
P/BV x 4.1 6.2 65.5% View Chart
Dividend Yield % 0.6 0.7 80.4%  

Financials

 SUVEN LIFESCIENCES   ALKEM LABORATORIES
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-18
ALKEM LABORATORIES
Mar-16
SUVEN LIFESCIENCES/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs2511,589 15.8%   
Low Rs1551,232 12.6%   
Sales per share (Unadj.) Rs49.1417.5 11.8%  
Earnings per share (Unadj.) Rs9.756.3 17.3%  
Cash flow per share (Unadj.) Rs11.464.7 17.6%  
Dividends per share (Unadj.) Rs1.5012.70 11.8%  
Dividend yield (eoy) %0.70.9 82.1%  
Book value per share (Unadj.) Rs60.3292.9 20.6%  
Shares outstanding (eoy) m127.28119.57 106.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.13.4 122.2%   
Avg P/E ratio x20.925.1 83.3%  
P/CF ratio (eoy) x17.821.8 81.7%  
Price / Book Value ratio x3.44.8 69.9%  
Dividend payout %15.422.6 68.4%   
Avg Mkt Cap Rs m25,825168,653 15.3%   
No. of employees `0001.1NA-   
Total wages/salary Rs m6139,171 6.7%   
Avg. sales/employee Rs Th5,832.6NM-  
Avg. wages/employee Rs Th571.5NM-  
Avg. net profit/employee Rs Th1,153.8NM-  
INCOME DATA
Net Sales Rs m6,25349,915 12.5%  
Other income Rs m2331,645 14.1%   
Total revenues Rs m6,48551,561 12.6%   
Gross profit Rs m1,9828,482 23.4%  
Depreciation Rs m2131,006 21.2%   
Interest Rs m46671 6.9%   
Profit before tax Rs m1,9558,451 23.1%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7181,606 44.7%   
Profit after tax Rs m1,2376,731 18.4%  
Gross profit margin %31.717.0 186.5%  
Effective tax rate %36.719.0 193.3%   
Net profit margin %19.813.5 146.7%  
BALANCE SHEET DATA
Current assets Rs m5,62227,062 20.8%   
Current liabilities Rs m1,16815,324 7.6%   
Net working cap to sales %71.223.5 303.0%  
Current ratio x4.81.8 272.7%  
Inventory Days Days8167 122.4%  
Debtors Days Days3641 87.0%  
Net fixed assets Rs m3,32512,610 26.4%   
Share capital Rs m127239 53.2%   
"Free" reserves Rs m7,54734,490 21.9%   
Net worth Rs m7,67435,027 21.9%   
Long term debt Rs m141,212 1.1%   
Total assets Rs m9,13554,387 16.8%  
Interest coverage x43.213.6 317.8%   
Debt to equity ratio x00 5.2%  
Sales to assets ratio x0.70.9 74.6%   
Return on assets %14.013.6 103.2%  
Return on equity %16.119.2 83.9%  
Return on capital %26.024.9 104.7%  
Exports to sales %012.9 0.0%   
Imports to sales %03.1 0.0%   
Exports (fob) Rs mNA6,461 0.0%   
Imports (cif) Rs mNA1,540 0.0%   
Fx inflow Rs m5,0666,563 77.2%   
Fx outflow Rs m2,0013,012 66.4%   
Net fx Rs m3,0653,552 86.3%   
CASH FLOW
From Operations Rs m6997,259 9.6%  
From Investments Rs m-61,864 -0.3%  
From Financial Activity Rs m-577-9,273 6.2%  
Net Cashflow Rs m116-150 -77.5%  

Share Holding

Indian Promoters % 63.4 66.9 94.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 33.1 -  
FIIs % 0.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 0.0 -  
Shareholders   37,287 68,381 54.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   MERCK  CIPLA  TORRENT PHARMA  ALEMBIC LTD  STERLING BIOTECH  

Compare SUVEN LIFESCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Jet Airways and Yes Bank - What's Next for these Beaten Down Stocks?(Podcast)

Jet Airways and Yes Bank, both once market darlings are now being shunned by market participants. The National Stock Exchange (NSE) exchange notified that the shares of the airline.

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

SUVEN LIFE Announces Quarterly Results (2QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, SUVEN LIFE has posted a net profit of Rs 180 m (down 43.3% YoY). Sales on the other hand came in at Rs 895 m (down 16.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

SUVEN LIFE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

Here's an analysis of the annual report of SUVEN LIFE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFE. Also includes updates on the valuation of SUVEN LIFE.

SUVEN LIFE Announces Quarterly Results (4QFY18); Net Profit Up 56.0% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, SUVEN LIFE has posted a net profit of Rs 625 m (up 56.0% YoY). Sales on the other hand came in at Rs 2 bn (up 18.6% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

More Views on News

Most Popular

The Best 4 Small-cap Stocks to Buy(The 5 Minute Wrapup)

Jun 3, 2019

In the sometimes good sometimes bad market of small caps, there are strong buying opportunities available today. But this great opportunity won't last forever.

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Top 7 Stocks to Profit from Modi's Repeat Performance(Profit Hunter)

Jun 3, 2019

The long-term India story looks promising with the Modi government back in power. Which stocks are likely to go up the most?

Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)

Jun 6, 2019

Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Jun 14, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES - VENUS REMEDIES COMPARISON

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS